Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03597438 · ClinicalTrials.gov registry record
National CounterACT Initiative
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 236
- Enrollment target
NCT03597438 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 236 participants.
The verdict
NCT03597438 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 236 participants
- Enrollment target
Study Summary
The purpose of the study is to determine in vitro effects on mitochondrial function of selected chemical agents in human cells, and assess the capability of a cell-permeable succinate prodrug to attenuate toxic effects The project aims at repurposing this recent pharmaceutical discovery, currently being developed for treatment of toxic exposure, for an expanded indication to treat chemically induced mitochondrial toxicity.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2024-02-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03597438
The ClinicalTrials.gov registry entry for NCT03597438 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03597438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03597438 about?
NCT03597438 is a clinical study titled "National CounterACT Initiative". The purpose of the study is to determine in vitro effects on mitochondrial function of selected chemical agents in human cells, and assess the capability of a cell-permeable succinate prodrug to attenuate toxic effects The project aims at repurposing this recent pharmaceutical discovery, currently b...
What is the current status of trial NCT03597438?
This trial is currently completed. The enrollment target is 236 participants. The study started on 2018-05-07. Estimated completion is 2024-02-22.
Who is sponsoring clinical trial NCT03597438?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.